180 related articles for article (PubMed ID: 7687728)
1. Reduction of myocardial infarct size in rabbits by ramiprilat: reversal by the bradykinin antagonist HOE 140.
Hartman JC; Wall TM; Hullinger TG; Shebuski RJ
J Cardiovasc Pharmacol; 1993 Jun; 21(6):996-1003. PubMed ID: 7687728
[TBL] [Abstract][Full Text] [Related]
2. Reduction of myocardial infarct size by ramiprilat is independent of angiotensin II synthesis inhibition.
Hartman JC; Hullinger TG; Wall TM; Shebuski RJ
Eur J Pharmacol; 1993 Apr; 234(2-3):229-36. PubMed ID: 8482328
[TBL] [Abstract][Full Text] [Related]
3. The role of bradykinin and nitric oxide in the cardioprotective action of ACE inhibitors.
Hartman JC
Ann Thorac Surg; 1995 Sep; 60(3):789-92. PubMed ID: 7545893
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of nitric oxide synthase prevents myocardial protection by ramiprilat.
Hartman JC; Kurc GM; Hullinger TG; Wall TM; Sheehy RM; Shebuski RJ
J Pharmacol Exp Ther; 1994 Sep; 270(3):1071-6. PubMed ID: 7523655
[TBL] [Abstract][Full Text] [Related]
5. Do angiotensin converting enzyme inhibitors limit myocardial infarct size?
Miki T; Miura T; Shimamoto K; Urabe K; Sakamoto J; Iimura O
Clin Exp Pharmacol Physiol; 1993 Jun; 20(6):429-34. PubMed ID: 8339466
[TBL] [Abstract][Full Text] [Related]
6. Apstatin, a selective inhibitor of aminopeptidase P, reduces myocardial infarct size by a kinin-dependent pathway.
Wolfrum S; Richardt G; Dominiak P; Katus HA; Dendorfer A
Br J Pharmacol; 2001 Sep; 134(2):370-4. PubMed ID: 11564655
[TBL] [Abstract][Full Text] [Related]
7. Attenuation of myocardial stunning by the ACE inhibitor ramiprilat through a signal cascade of bradykinin and prostaglandins but not nitric oxide.
Ehring T; Baumgart D; Krajcar M; Hümmelgen M; Kompa S; Heusch G
Circulation; 1994 Sep; 90(3):1368-85. PubMed ID: 8087948
[TBL] [Abstract][Full Text] [Related]
8. Paracrine systems in the cardioprotective effect of angiotensin-converting enzyme inhibitors on myocardial ischemia/reperfusion injury in rats.
Liu YH; Yang XP; Sharov VG; Sigmon DH; Sabbath HN; Carretero OA
Hypertension; 1996 Jan; 27(1):7-13. PubMed ID: 8591891
[TBL] [Abstract][Full Text] [Related]
9. Inhibitors of bradykinin-inactivating enzymes decrease myocardial ischemia/reperfusion injury following 3 and 7 days of reperfusion.
Schriefer JA; Broudy EP; Hassen AH
J Pharmacol Exp Ther; 2001 Sep; 298(3):970-5. PubMed ID: 11504792
[TBL] [Abstract][Full Text] [Related]
10. Ramiprilat attenuates hypoxia/reoxygenation injury to cardiac myocytes via a bradykinin-dependent mechanism.
Wall TM; Linseman DA; Hartman JC
Eur J Pharmacol; 1996 Jun; 306(1-3):165-74. PubMed ID: 8813629
[TBL] [Abstract][Full Text] [Related]
11. The possible role of bradykinin in the antiischemic activity of ACE-inhibitors.
Martorana PA; Schölkens BA
Agents Actions Suppl; 1992; 38 ( Pt 3)():98-102. PubMed ID: 1462888
[TBL] [Abstract][Full Text] [Related]
12. Role of bradykinin in myocardial preconditioning.
Wall TM; Sheehy R; Hartman JC
J Pharmacol Exp Ther; 1994 Aug; 270(2):681-9. PubMed ID: 8071859
[TBL] [Abstract][Full Text] [Related]
13. Effect of ramiprilat or captopril on myocardial infarct size: assessment in canine models of ischemia alone and ischemia with reperfusion.
Black SC; Driscoll EM; Lucchesi BR
Pharmacology; 1998 Jul; 57(1):35-46. PubMed ID: 9670211
[TBL] [Abstract][Full Text] [Related]
14. [Reduction of infarct size and remodeling after ramipril].
Martorana PA; Linz W; Schölkens BA
Z Kardiol; 1994; 83 Suppl 4():63-4. PubMed ID: 7856282
[TBL] [Abstract][Full Text] [Related]
15. Contribution by bradykinin to the natriuretic response to the angiotensin converting enzyme inhibitor ramiprilat in spontaneously hypertensive rats.
Sakamoto T; Chen C; Lokhandwala MF
Naunyn Schmiedebergs Arch Pharmacol; 1994 Jul; 350(1):84-9. PubMed ID: 7935859
[TBL] [Abstract][Full Text] [Related]
16. Endopeptidase inhibitors decrease myocardial ischemia/reperfusion injury in an in vivo rabbit model.
Schriefer JA; Broudy EP; Hassen AH
J Pharmacol Exp Ther; 1996 Sep; 278(3):1034-9. PubMed ID: 8819483
[TBL] [Abstract][Full Text] [Related]
17. Dose-dependent reduction of myocardial infarct mass in rabbits by the NHE-1 inhibitor cariporide (HOE 642).
Linz W; Albus U; Crause P; Jung W; Weichert A; Schölkens BA; Scholz W
Clin Exp Hypertens; 1998 Oct; 20(7):733-49. PubMed ID: 9764718
[TBL] [Abstract][Full Text] [Related]
18. Captopril potentiates the myocardial infarct size-limiting effect of ischemic preconditioning through bradykinin B2 receptor activation.
Miki T; Miura T; Ura N; Ogawa T; Suzuki K; Shimamoto K; Iimura O
J Am Coll Cardiol; 1996 Nov; 28(6):1616-22. PubMed ID: 8917279
[TBL] [Abstract][Full Text] [Related]
19. Comparison of renal hemodynamic effect of ramiprilat to captopril; possible role of kinins.
Chen K; Zimmerman BG
J Pharmacol Exp Ther; 1994 Aug; 270(2):491-7. PubMed ID: 8071842
[TBL] [Abstract][Full Text] [Related]
20. Attenuation of reperfusion arrhythmias by selective inhibition of angiotensin-converting enzyme/kininase II in the ischemic zone: mediated by endogenous bradykinin?
Shimada Y; Avkiran M
J Cardiovasc Pharmacol; 1996 Mar; 27(3):428-38. PubMed ID: 8907806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
